The dopamine transporter (DAT) regulates the clearance of dopamine (DA) released into the extracellular space and is an important site on which psychostimulants act to produce their effects. Here, we show that mitogen-activated protein kinase ( 
Introduction
Dopamine (DA) neurotransmission in the CNS is implicated in the regulation of motor activity, stress responsiveness, and motivational state (Giros and Caron, 1993; Hyman, 1996) . Dysfunction of DA signaling contributes to various psychiatric and neurological disorders, including Parkinson's disease, schizophrenia, and drug addiction (Self and Nestler, 1995; Hyman, 1996) . DA signaling is terminated by the DA transporter (DAT), an integral membrane protein that is a member of the Na ϩ -and Cl Ϫ -dependent cotransporter gene family (Cass et al., 1991; Amara and Kuhar, 1993) . Pharmacological blockade of DAT by psychostimulants inhibits the reuptake of DA from the extracellular space, resulting in increased extracellular DA levels and augmented receptor stimulation (Horn, 1990) . Although pharmacological and genetic ablation (Grace, 1995; Jones et al., 1998) studies indicate a critical role of DAT in the maintenance of DA neuronal homeostasis, the endogenous mechanisms regulating DAT expression and activity are poorly understood.
DAT is synthesized in the cell soma and transported to the plasma membrane for use. The biosynthetic recovery of DAT in vivo requires up to 2 weeks, suggesting the existence of posttranslational mechanisms that respond more rapidly to an increased demand for DA clearance (Fleckenstein et al., 1996) . Indeed, DA receptor stimulation and changes in second messenger production modulate DA uptake in vitro and in vivo (Meiergerd et al., 1993; Ortiz et al., 1995; Mayfield and Zahniser, 2001) . Kinase-mediated changes in the activity of DAT and other biogenic amine transporters have been reported (Melikian et al., 1994; Vaughan et al., 1997; Zhang et al., 1997; Apparsundaram et al., 1998; Ramamoorthy and Blakely, 1999) . PKC activation decreases DA transport capacity (V max ) with little change in substrate affinity (Copeland et al., 1996; Huff et al., 1997; . PKC activation also induces transporter phosphorylation and decreased DAT cell surface expression (Melikian et al., 1994; Pristupa et al., 1998; Daniels and Amara, 1999) . Inhibition of PKA or calmodulin protein kinase also alters DAT transport capacity (Uchikawa et al., 1995; Batchelor and Schenk, 1998) , suggesting a more global role of protein kinases in regulating DAT activity. Whether the effects of these kinases result from alterations in transporter phosphorylation or activation of other kinase cascades is unclear. N-terminal truncation of DAT has recently been shown to abolish phorbol ester-and substance P receptor-stimulated phosphorylation without impairing transporter internalization (Granas et al., 2003) .
Mitogen-activated protein kinases (MAPKs) are serinethreonine kinases that regulate gene transcription, cell growth, and differentiation (Schlessinger and Ullrich, 1992; Treisman, 1996) . Their involvement in the regulation of cytoskeleton dynamics and G-protein-coupled receptor (GPCR) signaling has been demonstrated (Drewes et al., 1992; Blenis, 1993) .
MAPKs are highly expressed in the CNS and are activated by various stimuli, including calcium, growth factors, and various GPCRs (Rosen et al., 1994; Vanhoutte et al., 1999) . Activation of MAPK may occur by both PKC-dependent and -independent mechanisms. D 2 DA receptor stimulation increases DA transport capacity and activates the MAPK cascade by increasing intracellular calcium and activating PKC (Yan et al., 1999; Mayfield and Zahniser, 2001 ). In addition, other GPCRs and ionotropic neurotransmitter receptors (Welch and Justice, 1996; Thompson et al., 2000; Liu et al., 2001 ) that activate MAPK profoundly alter DAT activity. In view of these findings and those demonstrating MAPK-induced phosphorylation of cytosketal proteins implicated in protein trafficking, we examined the involvement of MAPKs in regulating DA uptake and DAT trafficking. We show that MAPK inhibition decreases DA transport capacity in rat striatal synaptosomes and EM4 cells (Robbins and Horlick, 1998) stably expressing FLAG-tagged human DAT (hDAT). Confocal microscopy and biotinylation studies show that this decrease is associated with the clathrin-dependent redistribution of DAT from the plasma membrane to the cytosol. Furthermore, in contrast to MAPK inhibition, transient transfection of hDATexpressing cells with constitutively active MAPK kinase (MEK) results in overexpression of phosphorylated MAPK and increased DA transport.
Materials and Methods
Synaptosome preparation. Male Sprague Dawley rats (250 -300 gm; Charles River Laboratories, Wilmington, MA) were housed in a colony room maintained at constant temperature (20°C) and humidity for a week before experiments. Rats had ad libitum access to food and water, and a 12 hr light/dark cycle was used. Experiments were approved by the National Institute on Drug Abuse Animal Care and Use Committee. Rats were killed by decapitation, and their brains were removed to an icecooled dish. The striatum was dissected and placed in ice-cold Krebs'-Ringer's buffer (in mM: 125 NaCl, 1.2 KCl, 1.2 MgSO 4 , 1.2 CaCl 2 , 22 NaHCO 3 , 1 NaH 2 PO 4 , and 10 glucose, pH 7.4) containing 0.32 M sucrose and homogenized using a glass homogenizing tube and a Teflon pestle. After centrifugation at 1000 ϫ g for 10 min at 4°C, the pellet was discarded, and the supernatant was centrifuged at 16,000 ϫ g for 15 min. The P2 pellet was placed on ice until resuspension.
Immunoblot analysis of extracellular signal-regulated kinase 1 and 2 activity. Synaptosomes were incubated with the selective MEK inhibitors (Tocris, Ballwin, MO) 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto) butadiene (U0126) (50 M) and 2-(2-amino-3-methyoxyphenyl)-4H-1-benzopyran-4-one (PD98059) (50 M) (Alessi et al., 1995; Duncia et al., 1998) at 37°C for 30 min. The concentration used selectively inhibits phosphorylation of the p42 [extracellular signal-regulated kinase 2 (ERK2)] and p44 (ERK1) forms of MAPK (Cussac et al., 1999; Yan et al., 1999) . Because phosphatidylinositol 3-kinase (PI 3-kinase) activates MAPK in several cell lines (Hawes et al., 1995; Igishi and Gutkind, 1998) , the influence of the selective PI 3-kinase inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002; Tocris) (Vlahos et al., 1994) on MAPK activity was also assessed. After incubation, synaptosomal fractions were solubilized, and the protein concentration for each sample was quantified. Equal amounts of protein from the fractions were separated on 10% acrylamide gels and transferred to polyvinylidene difluoride membranes (Millipore, San Jose, CA). Phosphorylated MAPK was determined with a monoclonal antibody raised against the p42 and p44 forms phosphorylated on both threonine and tyrosine residues (New England Biolabs, Beverly, MA). Detection was performed by enhanced chemiluminescence with a horseradish peroxidase-labeled secondary antibody (Amersham Biosciences, Piscataway NJ). Total MAPK was revealed with a polyclonal antibody against unphosphorylated and phosphorylated forms of p42 and p44 (New England Biolabs) followed by enhanced chemiluminescence detection. Membranes were placed in a Fluor-S multi-imager (Bio-Rad, Hercules, CA), and band densities were determined using Quantity One software (Bio-Rad).
[ ]DA was determined in samples incubated at 4°C. The assay was terminated by placing the tubes on ice and adding 5 ml of ice-cold Krebs'-Ringer's buffer. The solutions were then filtered through Whatman (Clifton, NJ) GF/C glass microfiber filters presoaked in 0.1% polyethyleneimine to reduce nonspecific binding. After filtration, the filters were washed two times with 5 ml of ice-cold Krebs'-Ringer's buffer. They were placed in scintillation vials, and 3 ml of Bio-Safe II scintillation fluid (Research Biochemicals, Natick, MA) was added to each tube. Radioactivity was determined by liquid scintillation spectrometry. Kinetic parameters were determined by nonlinear regression fitting using Prism software (GraphPad; Microsoft, Redmond, WA).
Plasmid construction, transfection, and cell culture. The synthetic hDAT gene was tagged at the N terminus with a FLAG epitope and was subcloned into a bicistronic expression vector (Rees et al., 1996) , creating a construct that expresses the synthetic hDAT from a cytomegalovirus promoter and the hygromycin resistance gene from an internal ribosomal entry site as described previously (Saunders et al., 2000) . EM4 cells, human embryonic kidney (HEK) 293 cells stably transfected with a macrophage scavenger (R. Horlick, Pharmacopeia, Cranberry, NJ), were stably transfected with the FLAG-hDAT with LipofectAMINE (Invitrogen, San Diego, CA), and a stably transfected pool was selected in hygromycin (250 g/ml) as described (Ferrer and Javitch, 1998) . Cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS) at 37°C and 5% CO 2 . Previous studies have shown that addition of the N-terminal FLAG tag does not alter [ 3 H]DA uptake by the transporter. Similarly, the ability of the transporter to produce substrate-induced currents is unaltered (Saunders et al., 2000) .
An enhanced green fluorescent protein-C1-CLCA1 plasmid (pEGFP-C1-CLCA1) was prepared by amplifying clathrin LCA1 from plasmid pPPa1-2 with primers 5Ј-CATGCTCGAGTCATGGCTGAGTTGGATCC-3Ј and 5Ј-CATGGAATTGCTGGCTCTTCAATGCACC-3Ј. The resultant PCR product was cleaved with XhoI-EcoR1 and inserted into XhoIEcoR1-cleaved pEGFP-C1 (Clontech, Palo Alto, CA) to generate plasmid pEGFP-C1-CLCA1. The stable FLAG-hDAT-expressing EM4 cells were transiently transfected using the calcium phosphate transfection method with 1 g of pEGFP-C1-CLCA1 per 35 mm dish. The cells were treated with MAPK inhibitors 48 hours later as described above.
EM4 cells stably expressing FLAG-hDAT were transiently transfected with 3 g of wild-type MEK or the constitutively active MEK mutant S218E-S222D (S. J. Mansour, University of Colorado, Boulder, CO) using 15 l of LipofectAMINE (Invitrogen) per T75 flask. Previous characterization of this mutant in HEK 293 cells revealed a significant elevation of phosphorylated ERK2 relative to that of cells transfected with wild-type MEK (Mansour et al., 1994) . Cells were incubated with lipid-cDNA complexes in Opti-MEM medium for 5 hr at 37°C in a CO 2 incubator, and then medium was replaced with DMEM and F-12 containing 10% FBS. Forty-eight hours after transfection, cells were seeded into 24-well plates for [ 3 H]DA uptake or into six-well plates for immunoblotting.
[ 3 H]DA uptake in FLAG-hDAT cells. EM4 cells stably transfected with FLAG-tagged DAT were seeded into 24-well plates 24 hr before experiments and grown to confluence (ϳ250,000 cells per well). After 1 hr of serum starvation, cells were washed two times with Krebs' buffer (in mM: 120 NaCl, 4.7 KCl, 10 HEPES, 5 Tris, 2.2 CaCl 2 , and 10 D-glucose, pH 7.4) and then preincubated for 30 min with Krebs' buffer containing (in M): 50 ascorbic acid, 50 pargyline, and 1 2Ј-fluoro-3,4-dihydroxy-5-nitrobenzophenone at 37°C in the absence or presence of 50 M U0126 or PD98058. The cells were treated in quadruplicate wells with [ 3 H]DA (10 Ci/mmol; Amersham Biosciences) in the continued presence or absence of inhibitor and various concentrations of unlabeled DA (0.1-50 M). The reaction mixture was incubated for 5 min at 25°C and then aspirated to terminate uptake. After three 1 ml washes with ice-cold Krebs' buffer, cells were lysed with 300 l of 1% SDS. Radioactivity was measured in 4 ml of Bio-Safe II scintillation fluid (Research Biochemicals). Specific [ 3 H]DA uptake was defined as total uptake less nonspecific in the presence of 100 M cocaine.
[ 3 H]Leucine uptake in FLAG-hDAT cells.
[ 3 H]Leucine uptake was examined using the conditions described above. Uptake was initiated by the addition of 15 nM [ 3 H]leucine (PerkinElmer Life Sciences, Boston, MA) together with 100 M unlabeled leucine and terminated by three rapid washes with ice-cold Krebs' buffer. Nonspecific uptake was defined with parallel assays on ice.
Immunofluorescence and confocal microscopy. Cells were incubated with U0126 or PD98059 (50 M) at 37°C for 30 min. The steps for immunostaining were conducted at room temperature. The coverslips containing the cells (50 -70% confluent) were washed two times with PBS and fixed for 25 min with 4% paraformaldehyde. The cells were rinsed two times with PBS and blocked with 5% normal goat serum diluted in 0.05% Triton X-100 and PBS (PBST) for 1 hr. The blocking solution was aspirated, and the cells were rinsed once with PBST. The coverslips were incubated with primary antibody (anti-FLAG M-2 monoclonal antibody; Sigma, St. Louis, MO) at a 1:3000 dilution in PBST for 1 hr. The primary antibody was aspirated, and the cells were washed three times with PBST. The cells were incubated with secondary antibody [goat anti-mouse IgG (heavy and light chain) tetramethylrhodamine isothiocyanate; Kirkegarrd & Perry, Gaithersburg, MD] at a 1:200 dilution in PBST for 1 hr. The secondary antibody was removed, and cells were washed three times times with PBST and one time with PBS. Coverslips were then mounted onto slides with Crystal Mount (Biomedia, Foster City, CA) and allowed to dry. Confocal microscopy was performed on a Nikon (Melville, NY) Diaphot inverted microscope using a Bio-Rad MRC1024 confocal imaging system equipped with a kryptonargon laser and Lasersharp software (Bio-Rad). To minimize fluorescent bleed-through of the GFP emission into the red [tetramethylrhodamine (TMR)] image, images were obtained in a sequential manner. The GFP image was obtained using the 488 nm laser excitation line and a 522DF32 emission filter. The TMR image was obtained using only the 568 nm excitation wavelength with an HQ598DF40 emission filter. Images were obtained with a 100ϫ oil immersion objective with a z-axis resolution of 1 m unless otherwise stated. Confocal images were quantified using the ImageJ image analysis system, which determines the average fluorescent intensity (AFI) within a cursor-determined area. Two areas were identified and quantified for each cell: total cell and cytoplasm. Data were expressed as the ratio of cytoplasmic to total AFI. The AFI of DAT immunofluorescence was quantified by an experimenter blind to the treatment conditions.
Cell surface biotinylation and immunoblotting. EM4 cells stably transfected with FLAG-tagged DAT were seeded on six-well plates at a density of 1 ϫ 10 6 cells per well 24 hr before treatments. Cell surface biotinylation was performed as described by Apparsundaram et al. (1998) with some modifications. Cells were washed two times with Krebs' buffer (in mM: 120 NaCl, 4.69 KCl, 10 HEPES, 5 Tris, 2.19 CaCl 2 , and 10 D-glucose, pH 7.4) at 37°C and then preincubated for 30 min with Krebs' buffer at 37°C in the absence or presence of 50 M PD98059. Cells were washed quickly with ice-cold PBS containing 0.1 mM CaCl 2 and 1 mM MgCl 2 (PBS/Ca-Mg) and treated with sulfo-NHS-sulfo-S-S-biotin (NHS-SS) (1.5 mg/ml; Pierce, Rockford, IL) at 4°C for 1 hr in PBS/Ca-Mg. Cells transiently transfected with wild-type or constitutively active MEK were treated with sulfo-NHS-SS-biotin 48 hr after transfection. Biotinylating reagents were removed by washing at 4°C with 100 mM glycine in PBS/ Ca-Mg twice; the reaction was further quenched by incubation with 100 mM glycine for 30 min at 4°C. Cells were then quickly washed two times with ice-cold PBS/Ca-Mg before lysis with 1 ml of radioimmunoprecipitation assay buffer (20 mM Tris, 20 mM EGTA, 1 mM DTT, 1 mM benzamidine, and 1% Triton X-100) supplemented with protease inhibitors (100 M PMSF, 5 g/ml leupeptin, and 5 g/ml pepstatin) for 30 min at 4°C with constant shaking. Lysates were centrifuged at 14,000 ϫ g for 30 min at 4°C. Biotinylated and nonbiotinylated proteins were separated by incubation with ImmunoPure immobilized streptavidin beads (Pierce) for 1 hr at room temperature with constant mixing. Beads were washed three times with radioimmunoprecipitation assay buffer, and adsorbed proteins were eluted with Laemmli loading buffer containing 2-mercaptoethanol for 30 min at room temperature. Total cell lysates and biotinylated (cell surface) and nonbiotinylated proteins were separated by SDS-PAGE (7.5%) and immunoblotted with a rat monoclonal antibody directed against the N terminus of the hDAT (1:2000; Chemicon, Temecula, CA) using an HRP-conjugated goat anti-rat antibody (1:5000; Santa Cruz Biotechnology, Santa Cruz, CA). Immunoreactive bands were visualized with ECL on Hypersensitive ECL film (Amersham Biosciences). Band densities were determined using Scion-Image software (Scion Corp., Frederick, MD).
Results

Constitutive activation of MAPK in synaptosomes
Analysis of immunoblots with antibodies directed against the phosphorylated forms of ERK1 and ERK2 (p44 and p42 isoforms of MAPK) revealed the presence of labeled bands in untreated striatal synaptosomes, consistent with previous reports of constitutive MAPK activation in this brain region (Flood et al., 1998; Gerfen et al., 2002) . Figure 1 shows that incubation of synaptosomes with the MEK inhibitor U0126 significantly decreased phosphorylated ERK1 and ERK2 without affecting total MAPK levels (native and phosphorylated forms). A similar decrease was observed when striatal synaptosomes were incubated with PD98059. Incubation of synaptosomes with the PI 3-kinase inhibitor LY294002 did not alter the phosphorylation state of MAPK.
MAPK inhibition downregulates DA uptake in synaptosomes
Incubation of striatal synaptosomes with U0126 (50 M) decreased DA uptake. A significant reduction of DA uptake was apparent after 5 min of preincubation, and a maximum decrease of 56 Ϯ 2% was observed after 30 min (Fig. 2 A) . PD98059 also significantly reduced DA uptake, but the magnitude of this effect was less than that produced by U0126 (Fig. 2 A) .
Incubation of synaptosomes with varying concentrations of the MEK inhibitors revealed that the decrease in DA uptake was concentration-dependent (Fig. 2 B) . Concentrations as low as 0.1 M significantly decreased DA uptake, and a maximum decrease was observed after addition of a 50 M concentration of either agent. Kinetic analysis showed that both inhibitors significantly decreased transport capacity (V max ) with no apparent change in DA affinity (K m ). The V max values of DA uptake were reduced to 45 Ϯ 2 and 80 Ϯ 5% of control values after incubation with U0126 and PD 98059, respectively (Table 1 ). The effect of U0126 on DA uptake and MAPK phosphorylation was greater than that produced by PD98059, consistent with the differing effects of these agents on MEK-1 and -2. U0126 inhibits MEK-1 and -2, whereas PD98059 only prevents the activation and phosphoryla-tion of MEK-1 (Alessi et al., 1995) . In contrast to the marked effects of the MEK inhibitors, incubation (5-30 min) of synaptosomes with the p38 MAPK inhibitor 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (1.0 -50 M; Lee et al., 1999 ) did not affect [ 3 H]DA uptake, suggesting the lack of a role for the p38 MAPK cascade in the regulation of basal DA uptake (data not shown).
MAPK inhibition downregulates [
3 H]DA uptake in FLAG-hDAT cells Cells stably transfected with FLAG-hDAT were used to examine the mechanisms mediating the inhibition of DA uptake produced by MAPK inhibition. Incubation of cells with PD98059 (50 M) markedly decreased levels of p44 and p42 forms of MAPK with no change in total MAPK levels (data not shown). As in synaptosomes, both MEK inhibitors decreased [
3 H]DA uptake in FLAGhDAT cells. PD98059 decreased the V max to ϳ76% of control values, and U0126 decreased the V max of uptake to ϳ32% of control values (Table 2) . Thus, as in synaptosomes, the decrease in V max for PD98059 was less than that produced by U0126. Moreover, as in synaptosomes, no significant change in K m was observed in FLAG-hDAT cells. When PD98059 was only present during the uptake assay, [ 3 H]DA uptake was unaltered (109.2 Ϯ 4.4% of control; n ϭ 3), demonstrating that the effects of the MEK inhibitors on DA uptake do not result from a direct interaction with DAT. Incubation of cells with either U0126 (50 M; 93.5 Ϯ 2.3% of control; n ϭ 3) or PD98059 (50 M; 98.7 Ϯ 0.4%; n ϭ 3) for 30 min failed to alter [ 3 H]leucine uptake in EM4 cells, demonstrating that the effect of MAPK inhibition on DAT is not a nonspecific effect that is observed with all plasma membrane transporters.
MAPK inhibition decreases the cell surface distribution of FLAG-hDAT
A decrease in V max can arise from events that alter the turnover rate for DA transport or from a loss of transporter protein on the cell surface. To determine whether a reduction in the cell surface distribution of hDAT underlies the decrease in V max produced by MAPK inhibition, immunofluorescence confocal microscopy was used. Incubation of cells with either PD98059 (50 M) or U0126 (50 M) (data not shown) for 30 min resulted in a redis- tribution of the cellular expression pattern of hDAT. The immunofluorescence intensity of FLAG-hDAT on the cell surface was significantly reduced, and the cytosolic distribution of FLAGhDAT was increased (Fig. 3) .
MAPK inhibition promotes trafficking of FLAG-hDAT
To determine whether hDAT intracellular accumulation may represent a trafficking event, the influence of concanavalin A (ConA), a plant lectin that prevents internalization by stabilizing cell surface integrity (Lis and Sharon, 1986) , on PD98058-and U0126-induced redistribution of FLAG-hDAT (data not shown) was determined. Quantification of representative cells (Fig. 4) showed that the mean ratio of cytoplasmic to total AFI was 0.27 Ϯ 0.02 (n ϭ 15) for control cells. Preincubation of cells with PD98059 significantly increased this value to 0.69 Ϯ 0.04 (n ϭ 22). In cells pretreated with ConA before incubation with PD98059 (Fig. 4C) , the AFI ratio was 0.34 Ϯ 0.03 (n ϭ 15). This value was significantly different (Tukey's test, p Յ 0.01) from that of PD98059-treated cells, indicating that ConA attenuated the loss of cell surface DAT produced by MAPK inhibition. Preincubation with ConA alone (data not shown) did not alter the cell surface distribution of FLAG-hDAT Consistent with the findings of a decrease in [ 3 H]DA uptake and decreased hDAT cell surface expression, incubation of FLAG-hDAT cells with 50 M PD98059 for 30 min significantly decreased the level of hDAT protein recovered in the biotinylated (cell surface) fractions ( Fig. 5 ; 72 Ϯ 3.0% of control; n ϭ 4; p Յ 0.01, two-tailed t test).
Most plasma membrane proteins are internalized by clathrinmediated endocytosis. The involvement of clathrin-coated pits in mediating the increased cystolic expression evoked by MAPK inhibition was examined by coexpressing the FLAG-hDAT with GFPclathrin. Double-staining experiments were then performed to determine the effect of MAPK inhibition on the localization of FLAGhDAT and GFP-clathrin. Figure 6 shows only puncta of colocalization in untreated cells. After incubation with PD98059 for 30 min, extensive colocalization of GFP-clathrin with FLAG-hDAT is apparent, suggesting that hDAT traffics through the clathrin pathway. Together, these results suggest that the effects of MAPK inhibition result from a clathrin-dependent redistribution of the hDAT. 
Expression of constitutively active MEK increases [ 3 H]DA uptake in FLAG-hDAT cells
To evaluate whether MAPK stimulation increases the activity of hDAT, EM4 cells were transiently transfected with wild-type MEK or the constitutively active MEK mutant S218E-S222D (Mansour et al., 1994) . Consistent with a previous report (Mansour et al., 1994) , phosphorylated p44 and p42 forms of MAPK were markedly elevated in cells transfected with the S218E-S222D mutant relative to those transfected with the wild-type mutant. Immunoblot analysis of p44 and p42 MAPK revealed an ϳ20-fold increase relative to that of wild-type cells ( p Յ 0.01, twotailed t test; n ϭ 3; data not shown). Kinetic analysis of [ 3 H]DA uptake revealed a significant increase ( p Յ 0.05, two-tailed t test) in the V max of DA uptake in FLAG-hDAT cells transfected with constitutively active MEK ( Although biotinylation experiments revealed that the increase in DA uptake was associated with an increase in hDAT cell surface expression (113 Ϯ 4% of wild type; n ϭ 3), this effect did not reach statistical significance ( p ϭ 0.06, two-tailed t test).
Discussion
These studies demonstrate that the MAPK pathway is constitutively active in striatal synaptosomes and HEK-293 cells expressing an epitope-tagged hDAT. Inhibition of this pathway decreases DA uptake, an effect resulting from a decrease in transport capacity. Using confocal microscopy, we demonstrate that the decreased transport capacity is associated with the clathrin-dependent redistribution of hDAT from the plasma membrane to the cytosol. Furthermore, we show that expression of a constitutively active mutant of MEK kinase in FLAG-hDAT cells increases DA uptake, suggesting a direct correlation between DA uptake and MAPK activity.
DA transport across plasma membranes is a tightly regulated process involving transcriptional and post-transcriptional processes. In the CNS, presynaptic sites of DAT expression are located some distance from sites of gene transcription, limiting the temporal ability of cells to modulate transport capacity and DA uptake from the extracellular space. PKC activation decreases DA transport, whereas inhibitors increase transport (Melikian et al., 1994; Vaughan et al., 1997; Zhu et al., 1997; Pristupa et al., 1998) . Evidence that these effects result from alterations in transporter trafficking has been obtained (Pristupa et al., 1998; Daniels and Amara, 1999; Melikian and Buckley, 1999) . Although interactions between PKC and MAPKs have been reported (Treisman, 1996) , the role of MAPKs in regulating DA uptake and DAT cell surface expression has not been examined. We addressed this issue by using U0126 and PD98059, selective noncompetitive inhibitors of MEK, the dual-specificity kinase that phosphorylates ERK1 and ERK2 (Alessi et al., 1995; Duncia et al., 1998; Favata et al., 1998) .
PD98059 and U0126 decreased levels of phosphorylated ERK1 and ERK2 in striatal synaptosomes. These data are consistent with the documented biological activity of these agents and indicate constitutive activation of MAPK in this brain region. Although PI 3-kinase modulates MAPKs in several cell lines, LY294002, a selective PI 3-kinase inhibitor (Vlahos et al., 1994) , did not alter ERK1 and ERK2 phosphorylation, suggesting that . PD98059-induced internalization of FLAG-hDAT is clathrin-mediated. FLAG-hDAT cells were transiently transfected with the neuronal-specific GFP-clathrin light chain. Doublestaining experiments (red fluorescence for the FLAG-hDAT, green fluorescence for clathrin) were performed to determine colocalization of FLAG-hDAT and GFP-clathrin. Main panel, Confocal microscopy revealed little or no puncta of colocalization under control conditions. Inset, In FLAG-hDAT cells exposed for 30 min to 50 M PD9805, there is extensive colocalization (yellow) between GFP-clathrin and FLAG-hDAT, presumably at the level of endocytotic compartments. (Carvelli et al., 2002) and suggests that the effects of this kinase occur independently of the MAPK pathway.
Incubation of striatal synaptosomes with either U0126 or PD98059 decreased DA uptake. This effect resulted from a reduction in transporter capacity rather than a decrease in affinity. The maximum effect of U0126 was greater than that of PD98059, perhaps because U0126 inhibits both MEK-1 and -2, whereas PD98059 only inhibits MEK-1 (Alessi et al., 1995; Duncia et al., 1998) . These data indicate a novel mechanism of DAT regulation by MAPKs and suggest a critical role of the MAPK cascade in regulating presynaptic DA neurotransmission. Furthermore, they suggest that both p44 and p42 isoforms of MAPK regulate DA uptake. Whether the decrease in uptake results from the inhibition of MAPK within DA terminals or in other neurons that innervate the striatum remains an unanswered question. D 2 DA receptor antagonists decrease DA uptake in striatum, whereas D 2 receptor agonists increase it (Meiergerd et al., 1993; Cass and Gerhardt, 1994) . opioid receptor agonists as well as orphanin FQ also modulate DA uptake (Thompson et al., 2000; Liu et al., 2001) . Activation of each of these receptors results in the phosphorylation of p44 and p42 MAPK (Luo et al., 1998; Yan et al., 1999; Jordan et al., 2000) . The present findings, therefore, raise the intriguing possibility that GPCR regulation of DAT activity may occur at the level of the MAPK signaling cascade.
Various neurotransmitter transporters undergo internalization, and transporter trafficking may be one mechanism that permits rapid regulation of transporter activity (Bernstein and Quick, 1999; Daniels and Amara, 1999; Duan et al., 1999; Saunders et al., 2000) . Activation of PKC by phorbol ester decreases the V max of DA transport and causes a rapid redistribution of DAT from the plasma membrane to the cytosol (Melikian et al., 1994; Daniels and Amara, 1999) . Evidence that PKC regulates the activity and cell surface expression of serotonin transporters has also been obtained (Qian et al., 1997; Ramamoorthy et al., 1998; Bernstein and Quick, 1999) . More recent studies have shown that PI 3-kinase regulates the activity and trafficking of both DAT and the norepinephrine transporter (Apparsundaram et al., 2001; Carvelli et al., 2002) . Extracellular substrates also influence internalization of transporters, suggesting that trafficking may represent an important mechanism for the regulation of appropriate transport capacity (Qian et al., 1997; Duan et al., 1999; Saunders et al., 2000) .
Our studies in HEK 293 cells stably expressing FLAG-hDAT show that MAPK inhibition markedly decreases DA uptake and that this decrease is associated with a redistribution of immunofluorescence from the plasma membrane to the cytosol. A reduction in the V max of [ 3 H]DA uptake and increased cytosolic localization of FLAG-hDAT were observed after either U0126 or PD98059 treatment. Biotinylation studies confirmed that PD98059 reduces cell surface hDAT expression and that the magnitude of this effect is comparable with the decrease in V max produced by this agent. Our results extend those of a recent report (Rothman et al., 2002) , which showed that treatment with 10 M PD98059 decreased the B max for [ 125 I]3-(4-iodophenyl)-8-methyl-8-aza-bicyclo[3,2,1]octane-2-carboxylic acid methyl ester binding and indicate that this decrease may be mediated, in part, by the redistribution of DAT from the membrane to the cytosolic compartment. Additional studies, however, in striatal slices or in vivo are needed to test this hypothesis.
ConA binds to terminal mannose residues on cell surface glycoproteins and, by stabilizing their lateral mobility, prevents internalization (Lis and Sharon, 1986) . Preincubation of cells with ConA reduced the increase in cytosolic distribution of FLAGhDAT produced by both U0126 and PD98059, suggesting that hDAT redistribution reflects an internalization event. Internalization of many membrane proteins is mediated by formation of clathrin-coated pits. We found that colocalization of FLAGhDAT and clathrin is restricted to discrete puncta in the absence of MAPK inhibition. However, after treatment of cells with PD98059, extensive cytosolic colocalization of FLAG-hDAT and GFP-clathrin is seen.
PKC activation increases internalization of the hDAT by a clathrin-mediated process (Daniels and Amara, 1999) . A similar effect is observed in response to PI 3-kinase inhibition (Carvelli et al., 2002) . The finding that MAPK inhibition also induces the clathrin-dependent redistribution of hDAT suggests a more global role of kinase cascades in regulating DAT trafficking and DA neuronal homeostasis. Furthermore, it suggests that in contrast to PKC activation, which decreases DAT uptake and cell surface expression, constitutive MAPK activation, like that of PI 3-kinase, serves to inhibit translocation of DAT from the plasma membrane, to speed the return of internalized DAT to the membrane, or both.
In the absence of MAPK inhibitors, incubation of cells with ConA did not modify hDAT cell surface expression, suggesting that the fraction of recycling transporters in HEK 293 cells, in contrast to that in PC12 cells (Melikian and Buckley, 1999; Loder and Melikian, 2003) , is modest. Consistent with this hypothesis, confocal microscopy revealed only puncta of colocalized DAT and clathrin in untreated cells. Alternatively, ConA may decrease the translocation rate of DAT both to and from the plasma membrane, resulting in no net change in hDAT cell surface expression. The finding, however, that MAPK inhibition increases intracellular DAT levels strongly suggests that phosphorylated ERK1 and ERK2 regulate the amount of DAT expressed on the plasma membrane and that MAPK activation may be one mechanism that limits rapid and extensive hDAT recycling in HEK 293 cells. In this regard, it should be noted that levels of phosphorylated MAPK as well as the V max of DA uptake were significantly increased in cells transfected with a constitutively active MEK mutant. However, only a modest increase in hDAT cell surface expression was seen. This latter finding is not unexpected in view of the high level of hDAT cell surface expression apparent in wildtype cells (ϳ75%;). Nonetheless, the greater increase in transport than cell surface expression suggests that overexpression of phosphorylated MAPK increases DA uptake by affecting both transporter turnover and trafficking.
The mechanism by which MAPKs regulate DAT trafficking is unknown. The presence of consensus sites for PKC and other kinases on DAT suggests that alterations in the phosphorylation state of the transporter may occur in parallel with or lead to transporter redistribution. PKC phosphorylates DAT and other monoamine transporters (Qian et al., 1997; Vaughan et al., 1997) . The demonstration that an N-terminally truncated DAT is not phosphorylated but is, however, internalized after PKC activation suggests that although direct DAT phosphorylation may modulate trafficking, phosphorylation of other proteins (e.g., kinases and phosphatases) may be essential for DAT internalization (Granas et al., 2003) . Because PKC activation increases DAT internalization, as does inhibition of either MAPK or PI 3-kinase, if direct DAT phosphorylation is involved in both processes, then these latter kinases must act on different phosphorylation sites on DAT. Alternatively, if direct transporter phosphorylation modulates DAT activity, trafficking, or both, it may occur via kinases that are downstream of, or differentially regulated by, PKC compared with MAPK and PI 3-kinase. Regardless of the mechanism, the present findings suggest that MAPK activation may be an important mechanism that opposes PKC-mediated decreases in DA uptake and hDAT cell surface expression Redistribution of membrane proteins has been implicated in synaptic plasticity and neurotransmitter homeostasis (Man et al., 2000) . MAPKs have been implicated in the regulation of gene transcription, cell growth, and differentiation (Drewes et al., 1992; Blenis, 1993; Treisman, 1996) . The demonstration that MAPKs regulate DA uptake and DAT trafficking suggests that the MAPK cascade may contribute to the regulation of DA signaling and synaptic strength. Indeed, a recent study (Valjent et al., 2000) has shown that the DA uptake inhibitor cocaine stimulates MAPK. Moreover, cocaine increases DA uptake by promoting increased DAT cell surface expression (Daws et al., 2002) . The present data, therefore, suggest that cocaine stimulation of MAPK may be one mechanism by which cocaine increases DAT activity, thereby opposing the increase in extracellular DA produced by its direct blockade of transport.
